New hope for advanced cancers: first human trial of DXC008 begins
NCT ID NCT06926283
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 25 times
Summary
This early-phase study tests a new drug called DXC008 in people with prostate cancer or other solid tumors (like Ewing sarcoma) who have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 110 adults aged 18 to 75 will take part in this first-in-human trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.